Importantly, post-immunotherapy, the ferroptosis score of TP63+ SLC7A5+ HNSCC subpopulation was markedly different from that of the pre-treatment group (Figure 2L; Supplementary Figure S1D), suggesting that malignant cells may mediate ferroptosis to resist immunotherapy. The gene discussed is TP63; the disease is head and neck squamous cell carcinoma.